Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
- Chronic kidney disease (CKD) affects 850 million people worldwide,[i] 47 million in the EU,[ii] doubles a person’s risk for hospitalisation,[iii] and is a leading cause of death2
- Jardiance® (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically significant reduction in all-cause hospitalisations in people with CKD vs. placebo[iv],[v]
- The approval in CKD adds to existing indications in type 2 diabetes and heart failure;[vi] these interconnected conditions affect over 1 billion people worldwide[vii]
Bracknell, UK. July 25, 2023 – The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD)[viii], Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today. The approval has the potential to advance the standard of care for more than 47 million people in the EU living with CKD,2 and help relieve burden on healthcare systems by reducing the risk of all-cause hospitalisation for people with CKD.5,[ix],[x] With existing indications in type 2 diabetes and heart failure,6 empagliflozin could help manage the risks of cardio-renal-metabolic conditions, which are often interconnected. Cardio-renal-metabolic conditions affect over 1 billion people worldwide.7
“Living with chronic kidney disease can have a drastic impact on patients and their family’s lives. CKD not only affects individuals but also society overall due to the high economic burden to healthcare systems,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “As we deepen our knowledge in interconnected cardio-renal-metabolic conditions, we are very excited about the approval and the potential for empagliflozin to play an essential role in helping patients, their physicians and healthcare systems.”
“CKD is closely linked to other cardio-renal-metabolic conditions such as type 2 diabetes and heart failure – thus an integrated approach is vital for optimised treatment of these interconnected conditions. We look forward to continuing conversations with other regulatory bodies worldwide so that empagliflozin can be made available for as many people living with these conditions as quickly as possible,” continued Leonard Glass, M.D., F.A.C.E., senior vice president, Diabetes & Obesity Global Medical Affairs, Lilly.
